(Q47885076)

6 February 2018

title

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria (English)

1 reference

6 February 2018

main subject

phase I clinical trial

0 references

malaria

0 references

Plasmodium falciparum

0 references

1 reference

20

Carole Long

1 reference

6 February 2018

Elissa Malkin

1

1 reference

6 February 2018

Jinhong Hu

2

1 reference

6 February 2018

Zhen Li

3

1 reference

6 February 2018

Zhihui Chen

4

1 reference

6 February 2018

Xinling Bi

5

1 reference

6 February 2018

Zarifah Reed

6

1 reference

6 February 2018

Filip Dubovsky

7

1 reference

6 February 2018

Jian Liu

8

1 reference

6 February 2018

Qiang Wang

9

1 reference

6 February 2018

Xuegong Pan

10

1 reference

6 February 2018

Tom Chen

11

1 reference

6 February 2018

Birgitte Giersing

12

1 reference

6 February 2018

Yu Xu

13

1 reference

6 February 2018

Xin Kang

14

1 reference

6 February 2018

Jun Gu

15

1 reference

6 February 2018

Qian Shen

16

1 reference

6 February 2018

Kathryn Tucker

17

1 reference

6 February 2018

Eveline Tierney

18

1 reference

6 February 2018

Weiqing Pan

19

1 reference

6 February 2018

Zhifang Cao

21

1 reference

6 February 2018

language of work or name

English

0 references

publication date

16 October 2008

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

26

1 reference

6 February 2018

issue

52

1 reference

6 February 2018

page(s)

6864-6873

1 reference

6 February 2018

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Gamma-globulin and acquired immunity to human malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Apical membrane antigen 1: a malaria vaccine candidate in review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

7 January 2021

Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

7 January 2021

Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

7 January 2021

The multi-epitope polypeptide approach in HIV-1 vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.081

7 January 2021

10.1016/J.VACCINE.2008.09.081

Identifiers

DOI

1 reference

6 February 2018

release_ynqpwaacj5ggpmpdbyjoilt42u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ynqpwaacj5ggpmpdbyjoilt42u

24 November 2022

mapped directly with Wikidata item

1 reference

6 February 2018